Sino Biopharmaceutical Limited adheres to the vision of "Focusing on Innovation, Serving Patients, and Becoming a World-Leading Pharmaceutical Enterprise". For many years, it has continuously increased R&D investment to build an internationally competitive innovation system, and was selected as one of the "Top 3 in China's Pharmaceutical Innovation" by the China Pharmaceutical Innovation and Investment Index (China PIII).

The company focuses on four major therapeutic areas: neoplasm, liver disease, respiratory, and surgery/analgesia, forming an innovative drug R&D pipeline that covers multiple cutting-edge targets. It continues to build a competitive drug R&D platform, with investment in innovative drug R&D accounting for over 80% of total R&D spending, and its innovation pipeline ranks among the top globally. Its core enterprises, such as CTTQ Pharma and Beijing Tide Pharmaceutical, have undertaken more than 80 national and provincial/ministerial-level scientific research projects and have won major science and technology awards such as the "China Patent Gold Award" and the "National Science and Technology Progress Award".

The company has established multiple R&D and innovation centers in Beijing, Shanghai, Nanjing, Lianyungang, as well as in Europe and North America, with a global R&D team of over 2,900 people. We adhere to the concept of openness and win-win cooperation, striving to become a world-leading pharmaceutical enterprise. Through measures such as in-house innovation, major business development (BD) deals, international cooperation, and M&A, we actively supplement our innovation pipeline and technology platforms. At the same time, we connect extensively with renowned research institutions and scientific institutes at home and abroad, gathering global innovation resources to expand our international influence.

By the end of 2025, the company will have a cumulative total of 21 innovative products approved for marketing; in the next three years, more than ten innovative products are expected to enter the marketing stage. We look forward to bringing more and better medication options to patients as an increasing number of high-quality products enter their intensive harvest period, warming more lives with healthy technology.